The Leiden mutation of coagulation factor V in Hungarian SLE patients

Clinical and Applied Thrombosis/Hemostasis

Volumn 6, Issue 1, 2000, Pages 41-45

  Regéczy, Nóra ^a   Lakos, Gabriella ^a   Balogh, István ^a   Ajzner, Eva ^a   Kiss, Emese ^a   Szegedi, Gyula ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Activated Protein C Resistance; Antiphospholipid Antibody; Systemic Lupus Erythematosus; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; PHOSPHOLIPID ANTIBODY;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; FEMALE; FETUS WASTAGE; GENE MUTATION; HETEROZYGOTE; HUMAN; HUNGARY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA; THROMBOSIS;

ABORTION, SPONTANEOUS; ACTIVATED PROTEIN C RESISTANCE; ADULT; ANTIPHOSPHOLIPID SYNDROME; FACTOR V; FEMALE; GENE FREQUENCY; HETEROZYGOTE; HUMANS; HUNGARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PHENOTYPE; POINT MUTATION; PREGNANCY; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; SKIN DISEASES, VASCULAR; THROMBOSIS; VENOUS THROMBOSIS;

EID: 0343067129     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960000600107     Document Type: Article

References (34)

1. Alarcon-Segovia D, Delezé M, Oria CV, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine 1989;68:353.
2. Alarcon-Segovia D, Perez-Vazquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for he antiphospholipid syndrome within systemic lupus erythematosus. Semin Arth Rheum 1992;41:275.
3. Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993;342:341.
4. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a co-factor to activated protein C. Proc Natl Acad Sci USA 1993;90: 1004.
5. Koeleman BPC, Reitsma PH, Allaart CE, et al. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994;84:1031.
6. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517.
7. Tordai A, Klein I, Rajczy K, et al. Prevalence of factor V Leiden (Arg 506 Gln) in Hungary. Br J Haematol 1997;99:466.
8. Póka R, Ajzner É, Balogh I. Public health approach to activated protein C resistance assay. Am J Obstet Gynecol 1997;177:1271.
9. Balogh I, Pṕka R, Pfiegler Gy, et al. High prevalence of factor V Leiden mutation and prothrombin 20210A variant in Hungary. Thromb Haemost 1999;81:660.
10. Bontempo FA, Hassett AC, Faruki H, et al. The factor V Leiden mutation: spectrum of thrombotic events and laboratory evaluation. J Vasc Surg 1997;25:271.
11. Foley PW, Irvine CD, Standen GR, et al. Activated protein C resistance and peripheral vascular disease. Cardiovasc Surg 1997; 5:157.
12. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor Leiden (resistance activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2817.
13. Holm J, Hillarp A, Zöller B. et al. Factor V Q506 (resistance to activated protein C) and prognosis after acute coronary syndrome. Thromb Haemost 1999;81:857.
14. Ridker PM, Hennekens CH, Lindpainter K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Eng J Med 1995;332:912.
15. Garg UC, Arnett DK, Evans G, et al. No association between factor V Leiden mutation and coronary heart disease or carotid intima media thickness: The NIHLBI family heart study. Thromb Res 1998;89:289.
16. Brenner B, Mandel H, Lanir N, et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haemat 1997;97: 551.
17. Aznar J, Villa P, Espana F, Estellés A, et al. Activated protein C resistance phenotype in patients with antiphospholipid antibodies. J Lab Clin Med 1997;130(2):202.
18. Halbmayer WM, Haushofer A, Schön R, et al. Influence of lupus anticoagulant on commercially available kit for APC resistance. Thromb Haemost 1994;72:645.
19. Marciniak E, Romond E: Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant. Blood 1989;74:2426.
20. Oosting JD, Derksen RH, Bobbink JW, et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenic mechanism? Blood 1993;81:2618.
21. Pak HO, Perrotta AL. Venous thromboembolism in heterozygotes for factor V Leiden-The second hit hypothesis: A report of two patients and a review of the english-language literature. Clin Appl Thromb/Haemost 1997;3:210.
22. Roubey ASR. Autoentibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulant and other "antiphospholipid" antibodies. Blood 1994:84:2854.
23. Tosetto A, Missiaglia E, Gatto E, et al. The VITA project: Phenotypic resistance to activated protein C and factor V Leiden mutation in the general population. Thromb Haemost 1997;78:859.
24. Bick RL. The antiphospholipid thrombosis syndromes: A common multidisciplinary medical problem. Clin Appl Thromb Hemost 1997;3:270.
25. Hillarp A, Dahlback B, Zöller B. Activated protein C resistance: from phenotype to genotype and clinical practice. Blood Rev 1995; 9:201.
26. Fijnheer R, Horbach DA, Donders RC. Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus. Thromb Haemost 1996;76:514.
27. Sasso EH, Suzuki LA, Thompson AR, et al. Hereditary resistance to activated protein C:an uncommon risk factor for thromboembolic disease in lupus patients with antiphospholipid antibodies. Arthritis Rheum 1997;40:1720.
28. Brenner B, Vulfsons SL, Lanir N, et al. Coexistence of familial antiphospholipid syndrome and factor V Leiden: impact on thrombotic diathesis. Br J Haematol 1996;94:166.
29. Alarcon-Segovia D, Ruiz-Arguelles GJ, Garces-Eisele J, et al. Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome. J Rheumatol 1996;23:2162.
30. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271.
31. Harris EN, Gharavi AE, Boey ML. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;2:1211.
32. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in a patients homozygous for factor V Leiden mutation (activated protein C resistance). Blood 1995;85:1504.
33. Rees DC, Cox M, Clegg JB: World distribution of factor V Leiden. Lancet 1995;346:1133.
34. Herrmann FH, Koesling M, Schroder W, et al. Prevalence of factor V Leiden mutation in various populations. Genet Epidemol 1997; 14:403.